We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Medipan to Distribute Pronostics' Autoimmune Diagnostics in Germany and Austria

By HospiMedica staff writers
Posted on 17 Mar 2008
Pronostics Ltd. More...
(Cambridge, UK), a developer and manufacturer of next-generation multiplexed diagnostics, has signed a distribution agreement with Medipan GmbH (Berlin, Germany) for its autoimmune disease biomarker assays. Medipan, which distributes in vitro diagnostic tests in the field of autoimmunity, will have an exclusive license to sell Pronostics' UltraPlex ANA, coeliac, and thyroid assays in Germany and Austria.

Germany is Europe's largest market for diagnostic products. As part of the agreement, Medipan will market the assays to hospitals and large private laboratories. The deal could initially generate up to US$3.1 million (€2 million) in revenues.

UltraPlex assays provide a powerful tool for rapid, accurate, and inexpensive diagnosis of autoimmune diseases. UltraPlex is a highly accurate, digital multiplexing solution that enables tens to hundreds of tests to be performed simultaneously in a single assay using a microscopic bar-coding system. Pronostics lead product, the UltraPlex ANA assay, which consists of 11 tests in one, provides valuable time and cost savings compared to existing serial testing approaches using panels of human epithelial type 2 cell (Hep-2) screens and enzyme-linked immunosorbant assays (ELISAs). It allows hospitals and laboratories to perform fully automated profiles of patient samples and gives both quantitative and qualitative results for antibodies to autoimmune diseases.

Dr Dirk Roggenbuck, CEO of Medipan, said: "We are very pleased to have been chosen as the distributor for the UltraPlex range of autoimmune assays. The UltraPlex platform is more efficient and economical in the diagnosis of autoimmune diseases than conventional approaches, and we are looking forward to providing our customers with this improved service.”

Medipan develops and distributes in-vitro diagnostic tests, predominantly in the field of autoimmunity. Medipan's product portfolio provides a wide range of assays and it is expanding continuously. The company offers technical, medical, and scientific expertise and support ensuring the success of their partner's clinical and business objectives.


Related Links:
Pronostics
Medipan

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.